This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.
Ardelyx (ARDX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Ardelyx (ARDX) closed at $3.07, marking a +1.99% move from the previous day.
Cigna (CI) to Post Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
Cigna's (CI) fourth-quarter results are likely to reflect increased Evernorth and Cigna Healthcare profits.
Can Humana's (HUM) Q4 Earnings Beat on Healthcare Services?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect surging Healthcare Services profits on strong pharmacy business.
HCA Healthcare (HCA) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased equivalent admissions and outpatient surgery cases.
Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.
Elevance Health (ELV) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Is Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug
by Zacks Equity Research
The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.
Ardelyx (ARDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 86.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 0% and 307.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals (AERI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Aerie (AERI) delivered earnings and revenue surprises of 260.29% and 272.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Ardelyx (ARDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Implied Volatility Surging for Ardelyx (ARDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Is a Surprise Coming for Ardelyx (ARDX) This Earnings Season?
by Zacks Equity Research
Ardelyx (ARDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Editas (EDIT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) third-quarter earnings call, investor focus will likely be on the company's progress with the development of its lead pipeline candidate, EDIT-101.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.
Is the Options Market Predicting a Spike in Ardelyx (ARDX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -25.00% and 19.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?